5FU and Oxa paper by medivizor

Please feel free to read, share your thoughts, your stories and connect with others!
User avatar
beach sunrise
Posts: 539
Joined: Thu Mar 05, 2020 7:14 pm

5FU and Oxa paper by medivizor

Postby beach sunrise » Tue Sep 21, 2021 1:42 pm

8/19 RC CEA 82.6 T3N0M0
Neoadj 5FU/rad 6 wk
High dose IVC 1 1/2 wks before surgery. Continue still twice a week
Surg 1/20 APR - margins T4bN1a IIIC G2 MSI- 1/20 LN+ LVI+ PNI-
pre cea 24/post 5.9
FOLFOX
7 rds 6-10 CEA 11.4 No more
7/20 CEA 11.1, 8.8
8/20 CEA 7.8
9/20 CEA 8.8, 9, 8.6
10/20 CEA 8.1
11/20 CEA 8's
12/20 CEA 8's & 9's
ADAPT+++ TM drug
MHL1+
PMS2+
MSH2+
MSH6+
POLD1 , KRAS Q61H
Chem-sens test NCI "Test failed, neo adj CR worked. Not enough ca cells to test"

Rock_Robster
Posts: 591
Joined: Thu Oct 25, 2018 5:27 am
Location: Brisbane, Australia

Re: 5FU and Oxa paper by medivizor

Postby Rock_Robster » Wed Sep 22, 2021 9:07 am

Very interesting - thanks for sharing this. I’d tend to be careful with interpreting these, as it wasn’t a randomised controlled trial. The allocation of patients into the groups wasn’t done randomly, but instead based on clinical treatment decisions made by the oncologists at the time, which is highly likely to be confounded by a number of other factors (eg generally healthier/younger/stronger patients are more likely to be given oxaliplatin, compared to older patients or those with multiple comorbidities). Or conversely doctors may be more likely to prescribe oxy where they think a patient is at greater risk of recurrence/progression, partially explaining why oxaliplatin patients overall didn’t appear to do better.

While they’ve attempted to correct for this in the statistical analysis, unfortunately this type of trial still struggles to show more than correlation (ie I would be very hesitant to withhold oxaliplatin from any particular stage III patient without multiple RCTs. The difficulty here could be ethics, if FOLFOX is accepted as standard of care).
39M Australia
2018 Dx RC, 12cm high
Mod diff, EMVI+ LVI+. 4 liver mets
pT3N1aM1a Stage IVa. MSS NRAS G13R
CEA: Nov-18= 14, Mar-19= 2.4, Aug-19 <2.0, Mar-20=2.2, May-20=1.9, Jun-20=2.1, Sep-20: 2.1, Dec-20: 2.3, Mar-21=2.5, Jul-21=3.1
11/18 FOLFOX x6
3/19 Liver resection
5/19 25x pelvic radiation; complete met. response
07/19 ULAR w ileo, 1/27 LN+
08/19 Found liver spot
08/19 FOLFOX x1, FOLFOXIRI x1, FOLFIRI x5
12/19 Liver resection
02/20 Ileo reversed
03/20 NED (CT/PET/MRI/scope) - latest scans Jul-21

User avatar
beach sunrise
Posts: 539
Joined: Thu Mar 05, 2020 7:14 pm

Re: 5FU and Oxa paper by medivizor

Postby beach sunrise » Wed Sep 22, 2021 12:11 pm

Agreed. My thought about the paper was over 60 yrs old they really just don't know if it will help or just poison the person. There were a few questions about the sudy. Medivizor is good to read though.
AND, Oxa only poisoned me, did not phase cancer cells. So, I didn't get the 3-5% gain it supposedly declares.
8/19 RC CEA 82.6 T3N0M0
Neoadj 5FU/rad 6 wk
High dose IVC 1 1/2 wks before surgery. Continue still twice a week
Surg 1/20 APR - margins T4bN1a IIIC G2 MSI- 1/20 LN+ LVI+ PNI-
pre cea 24/post 5.9
FOLFOX
7 rds 6-10 CEA 11.4 No more
7/20 CEA 11.1, 8.8
8/20 CEA 7.8
9/20 CEA 8.8, 9, 8.6
10/20 CEA 8.1
11/20 CEA 8's
12/20 CEA 8's & 9's
ADAPT+++ TM drug
MHL1+
PMS2+
MSH2+
MSH6+
POLD1 , KRAS Q61H
Chem-sens test NCI "Test failed, neo adj CR worked. Not enough ca cells to test"


Return to “Colon Talk - Colon cancer (colorectal cancer) support forum”



Who is online

Users browsing this forum: Google [Bot] and 46 guests